Literature DB >> 26978874

TRANSITORY CONSECUTIVE ESOTROPIA AFTER AMITRIPTYLINE TREATMENT FOR NOCTURNAL ENURESIS -CASE REPORT.

E Daniela Cioplean, L Raluca Camburu.   

Abstract

We report the case of a 9-year-old child operated for intermittent exotropia and V-pattern with a good result 2 months after bilateral Lateral Rectus Muscle Recession. The binocular vision was restored in primary position and down-gaze with excellent stereopsis at near and distance and a deviation of +4 PD in primary position. Three months later, the patient developed a consecutive esotropia of + 18 PD in primary position with diplopia in all gazes triggered by Amitriptyline treatment prescribed one month earlier for nocturnal enuresis. Diplopia was solved in time after anticholinergic medication cessation. During the recovery period, Fresnell prisms have been used in order to eliminate diplopia. Three months after diplopia onset, the binocular vision was restored showing a transitory and reversible effect of the Amitriptyline treatment. Fusion vulnerability can be a possible risk factor in developing diplopia and esotropia in patients treated with anticholinergic drugs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26978874      PMCID: PMC5712929     

Source DB:  PubMed          Journal:  Rom J Ophthalmol        ISSN: 2457-4325


  5 in total

1.  Benztropine-induced Esotropia and Mydriasis.

Authors:  Sun-Young Oh; Byoung-Soo Shin; Yeon-Hee Lee; Ae Young Lee; Ji Soo Kim
Journal:  J Neuroophthalmol       Date:  2007-12       Impact factor: 3.042

2.  Anticholinergic esotropia.

Authors:  Jennifer M Anderson; Michael C Brodsky
Journal:  J Neuroophthalmol       Date:  2008-12       Impact factor: 3.042

3.  Esotropia in a child treated with a scopolamine patch for drooling.

Authors:  W V Good; L S Crain
Journal:  Pediatrics       Date:  1996-01       Impact factor: 7.124

4.  Combined pharmacotherapy for nocturnal enuresis.

Authors:  K Kaneko; S Fujinaga; Y Ohtomo; T Shimizu; Y Yamashiro
Journal:  Pediatr Nephrol       Date:  2001-08       Impact factor: 3.714

5.  Oxybutynin-associated esotropia.

Authors:  Elaine Y H Wong; Anton Harding; Lionel Kowal
Journal:  J AAPOS       Date:  2007-12       Impact factor: 1.220

  5 in total
  1 in total

1.  Convergence excess consecutive esotropia associated with 0.01% atropine eye drops usage in patients operated for intermittent exotropia.

Authors:  Mihir Kothari; Mohini Modak; Heena Khan; Shairin Jahan; Meghna Solanki; Vivek Rathod
Journal:  Indian J Ophthalmol       Date:  2020-04       Impact factor: 1.848

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.